Q2/2017 6/30/2017 EPS -0.760 ZacksConsensus -0.990 ActVsEst 0.230 - Beat
Windtree Therapeutics, Inc. (WINT)
Last windtree therapeutics, inc. earnings: 8/21 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
windtreetx.investorroom.com
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
WINT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WINT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WINT alerts
High impacting Windtree Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
WINT
News
- Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials ConferenceGlobeNewswire
- Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia [Yahoo! Finance]Yahoo! Finance
- Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial ArrhythmiaGlobeNewswire
- Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction [Yahoo! Finance]Yahoo! Finance
- Windtree Therapeutics, Inc. (NASDAQ: WINT) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
WINT
Analyst Actions
- 12/4/24 - HC Wainwright
WINT
Sec Filings
- 12/5/24 - Form 8-K
- 12/4/24 - Form 8-K
- 11/27/24 - Form 8-K
- WINT's page on the SEC website